{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:28:43Z","timestamp":1793737723198,"version":"4.6.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Myelofibrosis is a myeloproliferative neoplasm characterized by stem cell-derived clonal myeloproliferative and anomalous production of cytokines with genetic mutations in the JAK\/STAT signalling pathway playing a distinctive role in its pathophysiology. Diagnosis of MF presents a challenge due to vague and overlapping symptoms. The present strategy for managing MF is not well defined and relies on a symptomatic approach. Ruxolitinib is the first drug approved by the United States Food and Drug Administration in 2011. Drug Controller General of India approved Ruxolitinib in 2013 as a first-line treatment in patients with MF. This comprehensive survey aims to understand the MF patient journey and the perceptions\/practices of Indian hematologists\/oncologists regarding diagnosis, prognosis, and disease management of myelofibrosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A cross-sectional, multicentric, qualitative survey was conducted across 17 Indian cities from October 2021 to November 2021. One-on-one telephonic interviews were conducted using a structured questionnaire based on the study objective. Descriptive statistics were used to analyse the obtained data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Overall, 50 physicians and 154 patients (primary MF: 51, post-PV: 78 and post-ET: 25) completed the survey. The most common symptoms reported by patients and physicians at the time of diagnosis were, abdominal pain\/discomfort (81% vs. 70%), fatigue\/tiredness\/weakness (77% vs. 73%) and fever (54% vs. 48%). A 10-month delay was observed from the symptom onset to the final diagnosis and a further 9-month lag from final diagnosis to treatment initiation. In our survey, the physicians preferred Hydroxyurea (88%), blood transfusion (82%) and Ruxolitinib (78%) as the treatment regimen. The majority of the patients were aware of their treatment. Hydroxyurea constituted the predominant treatment option (<jats:italic>n<\/jats:italic>\u2009=\u200985); however, satisfaction was highest with Ruxolitinib (50%, <jats:italic>n<\/jats:italic>\u2009=\u200913). The physicians considered improving overall survival as an important treatment goal, while patients prioritized symptom relief.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The survey highlights the importance of understanding symptom burden and treatment goal perceptions in shaping management decisions. The results emphasize the need to align the physicians and patients on the actual treatment outcomes through patient education. Strengthening this alignment will enhance treatment adherence, improve patient satisfaction, and ensure better clinical outcomes, ultimately leading to a more patient-centred approach to managing the disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-14476-3","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T16:39:28Z","timestamp":1752165568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A comprehensive overview of patient journey and management decision pathway for myelofibrosis in India: INLAND survey"],"prefix":"10.1186","volume":"25","author":[{"given":"Prantar","family":"Chakrabarti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Bhave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulika","family":"Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"14476_CR1","doi-asserted-by":"publisher","first-page":"100715","DOI":"10.1016\/j.blre.2020.100715","volume":"42","author":"S Asher","year":"2020","unstructured":"Asher S, McLornan DP, Harrison CN. Current and future therapies for myelofibrosis. Blood Rev. 2020;42:100715.","journal-title":"Blood Rev"},{"issue":"13","key":"14476_CR2","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood. 2009;113(13):2895\u2013901.","journal-title":"Blood"},{"issue":"2","key":"14476_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15.","journal-title":"Blood Cancer J"},{"issue":"6","key":"14476_CR4","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667\u201379.","journal-title":"Blood"},{"issue":"3","key":"14476_CR5","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ajh.24978","volume":"93","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Nicolosi M, Mudireddy M, Szuber N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Pardanani A, Gangat N, et al. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. Am J Hematol. 2018;93(3):348\u201355.","journal-title":"Am J Hematol"},{"issue":"6","key":"14476_CR6","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1016\/j.clml.2021.01.025","volume":"21","author":"S Meckstroth","year":"2021","unstructured":"Meckstroth S, Wang R, Ma X, Podoltsev N. Patterns of care for older patients with myelofibrosis: A Population-based study. Clin Lymphoma Myeloma Leuk. 2021;21(6):e551\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"14476_CR7","first-page":"89","volume":"7","author":"TI Mughal","year":"2014","unstructured":"Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014;7:89\u2013101.","journal-title":"Int J Gen Med"},{"issue":"16","key":"14476_CR8","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507\u201313. quiz 2615.","journal-title":"Blood"},{"issue":"13","key":"14476_CR9","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/cncr.34205","volume":"128","author":"N Pemmaraju","year":"2022","unstructured":"Pemmaraju N, Verstovsek S, Mesa R, Gupta V, Garcia JS, Scandura JM, Oh ST, Passamonti F, D\u00f6hner K, Mead AJ. Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer. 2022;128(13):2420\u201332.","journal-title":"Cancer"},{"issue":"8","key":"14476_CR10","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1038\/s41375-024-02330-7","volume":"38","author":"S Koschmieder","year":"2024","unstructured":"Koschmieder S, Bose P, Ellis MH, Gupta V, Kiladjian JJ, Mascarenhas J, Mathews V, Passamonti F, Harrison C. Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group. Leukemia. 2024;38(8):1831\u20138.","journal-title":"Leukemia"},{"issue":"16","key":"14476_CR11","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood.2022017423","volume":"141","author":"F Passamonti","year":"2023","unstructured":"Passamonti F, Mora B. Myelofibrosis Blood. 2023;141(16):1954\u201370.","journal-title":"Myelofibrosis Blood"},{"issue":"1","key":"14476_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F, Harrison CN, Paquette R, Sun W, Naim A, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017;10(1):156.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"14476_CR13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-023-01471-z","volume":"16","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Mesa RA, Livingston RA, Hu W, Mascarenhas J. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety. J Hematol Oncol. 2023;16(1):82.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"14476_CR14","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1002\/cncr.34103","volume":"128","author":"L Masarova","year":"2022","unstructured":"Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer. 2022;128(8):1658\u201365.","journal-title":"Cancer"},{"key":"14476_CR15","doi-asserted-by":"crossref","unstructured":"Palandri F, Al-Ali HK, Guglielmelli P, Zuurman MW, Sarkar R, Gupta V. Benefit of early ruxolitinib initiation regardless of fibrosis grade in patients with primary myelofibrosis: A post hoc analysis of the Single-Arm phase 3b JUMP study. Cancers (Basel) 2023, 15(10).","DOI":"10.3390\/cancers15102859"},{"issue":"Supplement 1","key":"14476_CR16","doi-asserted-by":"publisher","first-page":"6649","DOI":"10.1182\/blood-2024-210274","volume":"144","author":"R Rampal","year":"2024","unstructured":"Rampal R, Marrone M, Morere L, Oladapo A, Suthar P, Sura T, Vasudevan A, Vredenburg M, Zeng J, Mascarenhas JO. Real-Word effectiveness of Pacritinib in patients with myelofibrosis who have thrombocytopenia and Anemia. Blood. 2024;144(Supplement 1):6649\u20136649.","journal-title":"Blood"},{"issue":"10","key":"14476_CR17","doi-asserted-by":"publisher","first-page":"e729","DOI":"10.1016\/S2352-3026(24)00212-6","volume":"11","author":"CN Harrison","year":"2024","unstructured":"Harrison CN, Mesa R, Talpaz M, Al-Ali HK, Xicoy B, Passamonti F, Palandri F, Benevolo G, Vannucchi AM, Mediavilla C, et al. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Haematol. 2024;11(10):e729\u201340.","journal-title":"Lancet Haematol"},{"key":"14476_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.4103\/ijmpo.ijmpo_88_17","volume":"39","author":"M Agarwal","year":"2018","unstructured":"Agarwal M, Malhotra H, Chakarborti P, Varma N, Mathews V, Bhattacharyya J, Seth T, Gyathri K, Menon H, Subramanian P, et al. Revised myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Indian J Med Pediatr Oncol. 2018;39:503.","journal-title":"Indian J Med Pediatr Oncol"},{"issue":"1","key":"14476_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.26050","volume":"96","author":"A Tefferi","year":"2021","unstructured":"Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021;96(1):145\u201362.","journal-title":"Am J Hematol"},{"issue":"6","key":"14476_CR20","doi-asserted-by":"publisher","first-page":"e569","DOI":"10.1016\/j.clml.2021.01.017","volume":"21","author":"S Singh","year":"2021","unstructured":"Singh S, Kaur K, Paul D, Jain K, Singh J, Narang V, Garg B, Sood N, Dhillon B. Clinical and molecular attributes of patients with BCR\/ABL1-negative myeloproliferative neoplasms in india: Real-world data and challenges. Clin Lymphoma Myeloma Leuk. 2021;21(6):e569\u201378.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"14476_CR21","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.clml.2023.01.012","volume":"23","author":"S Singh","year":"2023","unstructured":"Singh S, Singh J, Mehta A, Sharma R, Joshi K, Jain K, Paul D, Oberoi G, Jindal N, Dhillon B, et al. Distinctive attributes of Indian patients with classical BCR::ABL1 negative myeloproliferative neoplasms: unified clinical and laboratory data. Clin Lymphoma Myeloma Leuk. 2023;23(5):360\u2013e369361.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"14476_CR22","doi-asserted-by":"publisher","first-page":"S353","DOI":"10.1016\/j.clml.2019.07.370","volume":"19","author":"U Kulkarni","year":"2019","unstructured":"Kulkarni U, Venkatraman A, Korula A, Devasia A, Abubacker F, Lionel S, Srivastava A, Abraham A, Balasubramanian P, George B, et al. Clinical profile and symptom burden among patients with primary myelofibrosis presenting to a tertiary care center in India. Clin Lymphoma Myeloma Leuk. 2019;19:S353.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"14476_CR23","unstructured":"LIST OF APPROVED DRUG FROM 01-. 01-2013 to 31-12-2013 [https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadAlertsFiles\/New2013.pdf]"},{"key":"14476_CR24","doi-asserted-by":"publisher","first-page":"237437352110590","DOI":"10.1177\/23743735211059053","volume":"8","author":"CS Chang","year":"2021","unstructured":"Chang CS, Chen CW, Chiang IJ, Ku FC, Lee YM, Siddiqui A. A Cross-sectional study of patients and physicians on the impact of myeloproliferative neoplasms on patient health: the landmark survey from Taiwan. J Patient Exp. 2021;8:23743735211059053.","journal-title":"J Patient Exp"},{"issue":"10","key":"14476_CR25","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","volume":"96","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, Mathias J, Komatsu N, Boothroyd RN, Spierer A, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN landmark survey. Ann Hematol. 2017;96(10):1653\u201365.","journal-title":"Ann Hematol"},{"key":"14476_CR26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","volume":"16","author":"R Mesa","year":"2016","unstructured":"Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN landmark survey. BMC Cancer. 2016;16:167.","journal-title":"BMC Cancer"},{"issue":"9","key":"14476_CR27","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International working group for myeloproliferative neoplasms research and Treatment). Blood. 2010;115(9):1703\u20138.","journal-title":"Blood"},{"issue":"6","key":"14476_CR28","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","volume":"129","author":"E Rumi","year":"2017","unstructured":"Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129(6):680\u201392.","journal-title":"Blood"},{"issue":"13","key":"14476_CR29","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1002\/cam4.3004","volume":"9","author":"MA Yassin","year":"2020","unstructured":"Yassin MA, Taher A, Mathews V, Hou HA, Shamsi T, Tu\u011flular TF, Xiao Z, Kim SJ, Depei W, Li J, et al. MERGE: A multinational, multicenter observational registry for myeloproliferative neoplasms in asia, including middle east, turkey, and Algeria. Cancer Med. 2020;9(13):4512\u201326.","journal-title":"Cancer Med"},{"issue":"3","key":"14476_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/cncr.30325","volume":"123","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the united states: findings from the MPN landmark survey. Cancer. 2017;123(3):449\u201358.","journal-title":"Cancer"},{"issue":"33","key":"14476_CR31","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098\u2013103.","journal-title":"J Clin Oncol"},{"issue":"3","key":"14476_CR32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.htct.2020.10.966","volume":"44","author":"M Guaran\u00e1","year":"2022","unstructured":"Guaran\u00e1 M, Soares A, Daumas A, Biasoli I, Solza C. Myeloproliferative neoplasm symptom assessment Form - Total symptom score (MPN-SAF TSS) questionnaire: translation, cultural adaptation and validation to Brazilian Portuguese. Hematol Transfus Cell Ther. 2022;44(3):321\u20137.","journal-title":"Hematol Transfus Cell Ther"},{"key":"14476_CR33","doi-asserted-by":"crossref","unstructured":"G\u0103man MA, Scherber RM, Ursuleac I, Cri\u015fan AM, B\u0103deli\u0163\u0103 SN, Ionescu BO, Ghiaur AE, Br\u00eenz\u0103 M, P\u00eerciulescu N, Lasc\u0103r TO et al. Translation, cultural adaptation, and validation into Romanian of the myeloproliferative neoplasm symptom assessment Form-Total symptom score (MPN-SAF TSS or MPN-10) questionnaire. J Clin Med 2024, 13(11).","DOI":"10.3390\/jcm13113284"},{"issue":"9","key":"14476_CR34","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, et al. A Double-Blind, Placebo-Controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807.","journal-title":"N Engl J Med"},{"issue":"9","key":"14476_CR35","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, et al. JAK Inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787\u201398.","journal-title":"N Engl J Med"},{"issue":"12","key":"14476_CR36","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1182\/blood-2013-12-544411","volume":"123","author":"F Passamonti","year":"2014","unstructured":"Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T, Caramazza D, Pieri L, Rumi E, Gisslinger H, et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood. 2014;123(12):1833\u20135.","journal-title":"Blood"},{"issue":"12","key":"14476_CR37","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1007\/s00277-023-05458-1","volume":"102","author":"S Koschmieder","year":"2023","unstructured":"Koschmieder S, Isfort S, Schulte C, Jacobasch L, Geer T, Reiser M, Koenigsmann M, Heinrich B, Wehmeyer J, von der Heyde E, et al. Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were Na\u00efve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial. Ann Hematol. 2023;102(12):3383\u201399.","journal-title":"Ann Hematol"},{"issue":"5","key":"14476_CR38","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjh.16462","volume":"189","author":"HK Al-Ali","year":"2020","unstructured":"Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, le Coutre P, Garc\u00eda-Hern\u00e1ndez C, Zaritskey A, et al. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol. 2020;189(5):888\u2013903.","journal-title":"Br J Haematol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14476-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14476-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14476-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T04:45:56Z","timestamp":1757220356000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14476-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14476"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14476-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The survey was approved by the Royal Pune Independent Ethics Committee, Pune, Maharashtra, India (The Drugs Controller General of India, Registration Number: ECR\/45\/Indt\/MH\/2013\/RR-19 and RPIEC050921). The informed consent was obtained electronically from the survey participants before inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1164"}}